Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07787260

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity not receiving positive airway pressure (PAP) therapy. Eligible participants will be screened and randomized to the HDM1005 group or the placebo group at a ratio of 1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Obstructive Sleep Apnea (OSA) and Obesity Apnea Body Weight Dyssomnias Nervous System Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Peking University People's Hospital

Beijing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 75 years, male or female, at the time of signing the informed consent form.
  • BMI ≥ 28.0 kg/m² at both screening and randomization.
  • A self-reported change in body weight no more than 5% within 90 days before screening.
  • Subject has been diagnosed with obstructive sleep apnea (OSA) according to the International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria prior to screening, and has a centrally assessed apnea-hypopnea index (AHI) ≥15 events/hour on polysomnography (PSG) at screening.
  • Unable or unwilling to receive PAP therapy before screening, and not planning to initiate PAP therapy during the study period.

Exclusion criteria

  • History of any type of diabetes mellitus (history of gestational diabetes is permitted).
  • Have obesity induced by other endocrinologic disorders or by other medicine.
  • History of thyroid C-cell carcinoma, multiple endocrine neoplasia type 2 (MEN2) or relevant family history.
  • Diagnosis of central or mixed sleep apnea or Cheyne-Stokes respiration.
  • Respiratory or neuromuscular diseases judged by the investigator to potentially interfere with trial results.
  • Clinical abnormalities or diseases related to insomnia or excessive sleepiness (excluding OSA).
  • Uncontrolled hypertension prior to screening, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg (stable for 1 month if using antihypertensive drugs).
  • History of malignancy (except cured basal cell carcinoma) in the past 5 years or at the time of screening.
  • History of severe cardiovascular or cerebrovascular diseases within the past six months.
  • The subject has any other factors that may affect the efficacy or safety evaluation of this study, and is not suitable for participation in this study in the opinion of the investigator.

Treatment and study plan

HDM1005

Drug

Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

Placebo

Drug

Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.

Primary outcomes

  1. Percentage change in body weight from baseline at week 52

    Time frame: 52 week

  2. Change in AHI from baseline at week 52

    Time frame: 52 week

Secondary outcomes

  1. Percentage change in AHI from baseline

    Time frame: 52 week

  2. Proportion of participants with ≥50% reduction in AHI from baseline

    Time frame: 52 week

  3. Proportion of participants achieving the following criteria：AHI < 5; or 5 ≤ AHI ≤ 14 and Epworth Sleepiness Scale (ESS) score ≤ 10

    Time frame: 52 week

  4. Proportion of subjects whose body weight decreased by ≥ 5%, ≥ 10%, or ≥ 15% relative to baseline

    Time frame: 52 week

  5. Change in Epworth Sleepiness Scale (ESS) Score from Baseline at Week 52 of Treatment

    Time frame: 52 week

  6. Proportion of subjects reporting improvement in Patient Global Impression of Severity (PGIS)-OSA categories at Week 52 of treatment.

    Time frame: 52 week

  7. Incidence of adverse events (AEs)

    Time frame: 52 week

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Industry

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 26, 2026
Registry last updated
Aug 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.